Celltrion, Inc. Stock

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 18:00:00 2024-05-16 EDT 5-day change 1st Jan Change
191,500 KRW -0.78% Intraday chart for Celltrion, Inc. -0.73% -4.96%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 3,534B 2.62B 3.56B Sales 2025 * 4,201B 3.11B 4.23B Capitalization 39,491B 29.22B 39.77B
Net income 2024 * 552B 408M 556M Net income 2025 * 1,126B 833M 1.13B EV / Sales 2024 * 11.3 x
Net Debt 2024 * 544B 403M 548M Net cash position 2025 * 261B 193M 263M EV / Sales 2025 * 9.34 x
P/E ratio 2024 *
74.2 x
P/E ratio 2025 *
36.1 x
Employees 2,034
Yield 2024 *
0.23%
Yield 2025 *
0.24%
Free-Float 66.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.78%
1 week-0.73%
Current month+1.32%
1 month+11.99%
3 months+5.10%
6 months+13.72%
Current year-4.96%
More quotes
1 week
188 300.00
Extreme 188300
195 400.00
1 month
171 000.00
Extreme 171000
197 000.00
Current year
169 700.00
Extreme 169700
241 000.00
1 year
131 000.00
Extreme 131000
241 000.00
3 years
131 000.00
Extreme 131000
283 276.77
5 years
121 026.29
Extreme 121026.2888
372 915.00
10 years
27 751.54
Extreme 27751.5426
372 915.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 07-04-23
Director of Finance/CFO 49 -
Chairman 66 -
Members of the board TitleAgeSince
Director/Board Member 73 -
Chairman 66 -
Director/Board Member 66 -
More insiders
Date Price Change Volume
24-05-17 191,500 -0.78% 1,000,223
24-05-16 193,000 +1.10% 466,199
24-05-14 190,900 +0.05% 277,583
24-05-13 190,800 -1.09% 443,306
24-05-10 192,900 +1.69% 715,282

End-of-day quote Korea S.E., May 16, 2024

More quotes
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
191,500 KRW
Average target price
232,471 KRW
Spread / Average Target
+21.39%
Consensus
  1. Stock Market
  2. Equities
  3. A068270 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW